Cernuschi, T; Gaglione, S; Bozzani, F; (2018) Challenges to sustainable immunization systems in Gavi transitioning countries. Vaccine, 36 (45). pp. 6858-6866. ISSN 0264-410X DOI: https://doi.org/10.1016/j.vaccine.2018.06.012

Downloaded from: http://researchonline.lshtm.ac.uk/4649538/

DOI: https://doi.org/10.1016/j.vaccine.2018.06.012

Usage Guidelines:

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Challenges to sustainable immunization systems in Gavi transitioning countries

Tania Cernuschi a,⇑,1, Stephanie Gaglione b,1, Fiammetta Bozzani c

a World Health Organization, Geneva, Switzerland
b University of Toronto, Canada
c London School of Hygiene & Tropical Medicine, London, UK

ARTICLE INFO

Article history:
Received 12 January 2018
Received in revised form 24 May 2018
Accepted 4 June 2018
Available online 27 September 2018

Keywords:
Gavi transition
Sustainability
Immunization
Middle-income countries

ABSTRACT

The Global Vaccine Action Plan 2011–2020 (GVAP) aims to extend the full benefit of vaccination against vaccine-preventable diseases to all individuals. More than halfway through the Decade of Vaccines, countries classified as Middle-Income by the World Bank struggle to achieve several GVAP targets. Countries transitioning from Gavi, the Vaccine Alliance, represent a key sub-group of Middle Income Countries. Through a review of available literature on the subject, this study documents the lack of comparative analyses on immunization system performance in countries transitioning from Gavi support. Despite increased emphasis on the importance of programmatic sustainability beyond financing through the Gavi 2016–2020 Strategy and availability of data, existing literature has predominantly documented challenges related to domestic financing of immunization.

This study complements a review of current literature with an analysis of country assessments conducted by immunization partners since 2011, in an effort to document programmatic challenges related to decision-making for immunization policy, delivery of services, and access to affordable and timely supply in Gavi transitioning countries.

In light of the findings, we suggest continued systematic compilation of country performance data beyond financing to inform policy-making, in particular for: (i) development of a more nuanced theory of change towards sustainable immunization programmes and (ii) measurement of progress and key areas for attention and investment.

© 2018 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND IGO license. (http://creativecommons.org/licenses/by-nc-nd/3.0/igo/).

1. Introduction

Over the past decade, Middle Income Countries’ (MICs) access to vaccines has gained global attention. MICs struggle to achieve the targets set forward in the Global Vaccine Action Plan 2011–2020 (GVAP) and most either lack or will soon lose external financial and technical support [1–3].

As of July 2017, of 109 countries classified as MICs (GNI per capita between US$ 1006 and US$ 12,235) [4] by the World Bank, 42 receive financial and programmatic support through Gavi, the Vaccine Alliance [5]. Nevertheless, 26 of these countries have either transitioned or will soon transition from Gavi support [6]. As several countries with large populations below the poverty level have achieved middle-income status, MICs are now home to two-thirds of the world’s poorest people and account for two-thirds of deaths in children under the age of five [7].

According to the current Gavi transition and eligibility policies, a country enters a five year ‘transition phase’ when its average GNI per capita over three years equals or exceeds an eligibility threshold amount (US$1580 since 2015) [8]. Post-transition, countries do not receive further support from Gavi, although they may benefit from Gavi-comparable vaccine prices as well as limited alternative support from development partners [9]. Gavi transitioning countries represent a key sub-group of MICs where the sustainability of immunization efforts is at stake.

Since 2011, immunization program assessments (transition assessments) have been conducted in these countries to identify challenges to transition. The assessments are led by national...
immunization programs with support from Gavi [10]. Following assessments, Gavi supports the country in developing a transition plan, consisting of short- to medium-term investments by the government and Gavi to address potential sustainability issues. To date, results of these transition assessments and plans have not been systematically compiled and analyzed for cross-country comparison, and existing literature on programmatic immunization challenges affecting transitioning countries is limited. This study aims to document and begin addressing this gap in order to inform policy-making for sustainable immunization programmes.

2. Methodology

2.1. Literature review

A systematic literature review was carried out in May 2016 to retrieve existing comparative analyses of programmatic performance for Gavi transitioning countries, in order to identify commonly reported challenges. Two sources of information were examined: (1) published peer-reviewed articles and (2) Gavi documents. The peer-reviewed literature search was restricted from January 2009 to the present, reflecting the time during which transition policies were designed.

For published literature, the following search strategy was employed in PubMed: (sustainability OR challenges) AND (immunization OR vaccination) AND (Gavi) AND (graduation OR transition OR middle-income). Articles meeting the following criteria were included:

- Discussion of Gavi transition or graduation policies and the resulting impact on transitioning countries;
- Focus on one or more specific challenge areas (e.g. financing, supply chain, health workforce) in transitioning, lower-middle, and middle-income countries;
- Focus on the progression or transition of lower-middle and/or middle-income countries in developing sustainable and independent immunization programmes;
- Reference documents guiding the formation and progress of the graduation and transition programmes).

Articles in languages other than English, focussing on public health issues other than immunization, discussing immunization broadly without focussing on transition, and/or looking at a single vaccine-preventable disease were instead excluded.

Gavi documents were retrieved from the Gavi Programme and Policy Committee (PPC) webpage and WHO archives [11]. For the period of January 2009 to May 2016, the Committee minutes and Gavi Board meeting agendas were searched for the words “eligibility”, “transition”, and “graduation,” and matching background and supporting documents were retrieved from WHO archives. Relevant transition-related policies were additionally extracted from the library of policies on Gavi’s webpage (2009-2015) [12].

Fig. 1 illustrates the selection process and distribution of documents. Noting the estimated equivalence in quality, high variation in focus, and overall low number of peer-reviewed and Gavi documents retained for analysis, the articles were considered equally in the assessment. Findings were independently extracted from each document and compared, to generate a consensus on availability of information.

2.2. Analysis of country assessments and plans

As a second step, all Gavi transition assessments [15], transition plans [13] available to WHO as of May 2016 were reviewed. Assessments and plans were retrieved from the Expanded Programme on Immunization Team (EPI) in the WHO Immunization, Vaccines, and Biologicals Department (IVB). Table 1 provides a list of transitioning countries assessed by this study.

Rather than follow a strictly defined template, assessments are generated from a high-level guide that is flexibly adapted to each country’s circumstances. Information gaps were thus anticipated and addressed with additional sources of information (Table 2).

Transition assessments, transition plans, and supplemental sources of information were analyzed to understand country progress towards immunization related targets across four programmatic areas: (i) decision-making, (ii) political commitment and financial sustainability, (iii) demand for and equitable delivery of vaccines, and (iv) access to timely and affordable supply. These areas represent key pillars of the Immunization Partners’ Shared Strategy for Sustainable Access to vaccines in MICs, referred to as the MIC Strategy, endorsed by the WHO Strategic Advisory Group of Experts in Immunization (SAGE) in April 2015 [3]. While the MIC Strategy Framework was not developed specifically to analyse the sustainability of immunization programmes in Gavi transitioning countries, the framework was jointly developed by international partners and middle-income countries (including several supported by Gavi), to address concerns of MICs that are financing immunization efforts with national resources. The Framework thus provides a reasonable indication of sustainability challenges for this analysis.

Within this framework, specific indicators and targets were used to measure performance and challenges in study countries. In the absence of universally accepted standards, the indicators and targets used are either commonly accepted (e.g. GVAP targets) or derived from median values/reported challenges in sample countries. Basic statistical analysis was performed to determine the share of Gavi countries meeting, or failing to meet, targets. Thematic content analysis of qualitative information available in Fig. 1. Literature review flow diagram.
transition assessments and plans was further completed following the MIC Strategy Framework’s programmatic areas. Finally, the initiatives identified in the plans were matched to needs identified in the transition assessments.

2.3. Limitations

Several methodological limitations are noteworthy. The study surveys 15 of 26 Gavi transitioning countries, since transition assessments were not completed or available at the time of analysis for the remaining 11 countries (India, Lao PDR, Solomon Islands, Nigeria, Nicaragua, Cuba, Indonesia, Kiribati, Timor-Leste, Vietnam, Ukraine). Noting that several large countries are excluded, the data may overlook challenges impacting a significant share of the transitioning country population.

Moreover, there is currently a lack of consensus within Gavi on the path to sustainable immunization programs and thus on related criteria and indicators. While the MIC Strategy and GVAP provide a useful framework for analysis, the indicators and targets used in this analysis were not specifically developed to study Gavi transitioning countries and important considerations may be overlooked.

Finally, the lack of standardized templates and processes coupled with changing assessment teams impacts the comparability of assessment data.

These limitations could be addressed as data becomes increasingly available, Gavi develops a more targeted theory of change, and related monitoring/evaluation frameworks and targeted tools are developed to assess progress towards sustainability of immunization in transitioning countries.

3. Results

3.1. Literature review

The literature search produced a total of 52 documents, of which 42 were retained for analysis (see Table S1 for a summary of results). Gavi documents focus exclusively on transitioning countries, while peer-reviewed articles include analyses of Gavi-ineligible MICs. However, both Gavi publications and peer-reviewed literature focus heavily on appraising financial challenges for countries [3,9,13–17].

When reviewing the broader performance of immunization programmes in Gavi transitioning countries, most papers use the third dose of Diphtheria, Tetanus, and Pertussis (DTP3) immunization coverage as a proxy for overall programme impact without reviewing specific programmatic challenges. There are two exceptions: a Gavi document [14] and a peer-reviewed article [16] that review the transition experience of six countries (Angola, Bhutan, Republic of Congo, Georgia, Moldova, and Mongolia). Nonetheless,
while these two articles offer a useful view on country procurement practices, national regulatory authorities and country capacity for immunization planning and advocacy, they provide examples of issues rather than a comprehensive review of countries' challenges. One article elaborating on the rationale for recent Gavi transition policy updates also provides a high-level discussion of programmatic challenges [13]. However, aside from a list of established National Immunization Technical Advisory Bodies (NITAGs), the article does not provide a comprehensive analysis beyond financing challenges.

Gavi documents supporting access to Gavi-like prices provide data on the number of countries with potential payment and procurement inefficiencies and stress vaccine pricing as key factors affecting countries' ability to sustainably finance programmes [9,15].

A more systematic, although limited, analysis of immunization programmes is provided in an article addressing challenges experienced by the broader middle-income country group [18]. Here, Gavi transitioning countries do not receive special attention and it is thus not possible to identify unique constraints.

Finally, two papers specifically focused on national decision-making processes provide a review of available information from country case studies (15 countries) [19] or country interviews (95 countries) [20] to understand factors affecting decision-making on new vaccine adoption in low- and middle-income countries. These papers conclude that the local burden of disease data, vaccine prices and the cost implications of adopting a new vaccine are of particular importance in new vaccine adoption decisions in lower-middle-income countries (LMICs) and that the underlying driver for vaccine adoption decisions in Gavi-eligible countries was the desire to seize windows of opportunity for Gavi funding [19,20].

3.2 Analysis of country assessments and plans

Tables 3–5 provide results of the analysis. The online Appendix provides further detail.

3.2.1 Decision-making processes

The analysis first examined decision-making processes determining a country's capacity to undertake timely and evidence-based immunization policy and programmatic choices. Effective immunization decision-making is particularly important for countries that fully fund immunization programs and thus require strong evidence to secure sufficient domestic financial resources while relying less on international recommendations for immunization policies [20]. NITAGs are formal multidisciplinary bodies of national experts that aim to provide independent, evidence-based guidance to national policymakers on immunization-related decisions [21]. WHO recommends the establishment of NITAGs to enable governments to develop objective policies independent of external influence and to improve evidence-based decision-making on immunization [21]. Although most transitioning countries have progressed toward establishing NITAGs in line with GAVP targets, 60% of the countries under study lack a functional NITAG, particularly African countries [21]. Forty percent of transition assessments note issues in this area and this issue was not addressed by transition plans for only 3 countries. Transition plans generally present two types of support activities in this area: (a) establishing a NITAG and (b) enhancing access and use of disease surveillance data to support evidence-based decisions.

3.2.2. Political commitment and financial sustainability

With a loss of financial support from Gavi, transitioning countries must primarily rely on domestic resources to fund immunization services. Thirteen of the fifteen countries under study have a budget line for immunization as per GVAP recommendations and 62% finance a large portion of both routine immunization and related vaccines with government sources. Nonetheless, significant variation exists, with highest coverage in the American region. Nearly half of sample countries have defaulted at least once on Gavi co-financing requirements, particularly countries in the African region, and 67% of transition assessments report shortfalls in financing for immunization.

Transition plans largely recognize these well-understood weaknesses, recommending the construction of legal frameworks to ensure the political priority of immunization as well as the development of resource mobilization strategies linked to updated financial projections, cost and economic analyses, and fiscal space assessments.

3.2.3. Demand for and equitable delivery of vaccines

The analysis of demand for and equitable delivery of vaccines indicates that only 25% of countries under study have not reported major data quality issues and that two thirds of countries lack human resources to adequately provide quality health services, including immunization. Only 38% of countries have a communication plan for immunization activities, with the highest investment in communication noted in the African region. Vaccine management is problematic in 60% of countries and, on average, countries have experienced more than one stock-out per year between 2010 and 2015, with the most concerning results noted in the European region. Hesitancy among vaccine users is also flagged by most study countries (92%) and appears to be an important area of concern.

Transition assessments have identified challenges with data management, communication, human resources for health and supply chain in 60, 80, 67 and 80% of countries, respectively. To address these concerns, transition plans incorporate the following initiatives: training in data management and use (including support to implement electronic data systems at the community level), activities to develop national communication strategies and targeted media (i.e. posters, radio and television clips), communication training programs for key health officials, and capacity-building activities to train human resources on cold chain logistics and basic immunization practices. Overall, 19 of 45 issues identified across 11 countries are not explicitly addressed by transition plans.

3.2.4. Access to timely and affordable supply

According to data from the Gavi transition assessments and from the WHO Regulatory Systems Strengthening team, nearly half of the study countries utilize a mixed-procurement method to ensure timely access to affordable supply, procuring Gavi-funded vaccines and occasionally other routine vaccines through the UNICEF Supply Division (SD).

Transition assessments have evaluated whether countries procuring partly or fully through the United Nations (UN) can continue to do so following the termination of Gavi support. Only 4 out of 14 countries that procure through a UN organization will face barriers in continuing to use UN procurement due to national legislation requiring local procurement of vaccines.

Transition assessments have also evaluated the capacity of self-procuring or prospective self-procuring countries. The assessments report critical self-procurement capacity issues in 7 out of 9 applicable countries. Collectively, across all procurement methods, 73% of countries under study have identified at least one red flag in their current procurement practices. Beyond procurement, most transition assessments also noted barriers to accessing affordable vaccine pricing.

Transition plans are largely individualized in addressing procurement challenges and include activities such as training on
procurement methods, improving registration procedures, mid-level management training, improving the government understanding of UNICEF procurement processes, and enabling timely procurement of traditional and new vaccines.

To conclude, the analysis reviewed the strength of National Regulatory Authorities (NRAs), which are essential for assuring the safety, efficacy and quality of vaccines used in national immunization programmes [22]. WHO has developed standard criteria for evaluating NRAs across six key regulatory functions: marketing authorization and licensing; post-marketing surveillance; NRA lot release, laboratory access; regulatory inspections; and regulatory oversight of clinical trials [22]. A review of existing NRA

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Target Description</th>
<th>Rationale for choice of Target</th>
<th>Source</th>
<th>Year of data</th>
<th>Countries with Data (%)</th>
<th>Countries fulfilling Criteria, # (%)</th>
<th>AFRICA</th>
<th>AMERICAS</th>
<th>EUROPE</th>
<th>SOUTH-EAST ASIA</th>
<th>WESTERN PACIFIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decision-Making</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NitAG Existence</td>
<td>Countries have a NitAG</td>
<td>GVAP Indicator (1)</td>
<td>JRF</td>
<td>2015</td>
<td>15 (100%)</td>
<td>10 (67%)</td>
<td>0/3</td>
<td>2/3</td>
<td>5/5</td>
<td>2/2</td>
<td>1/2</td>
</tr>
<tr>
<td>NitAG Functionality</td>
<td>Countries have a functional NitAG</td>
<td>GVAP Indicator (3)</td>
<td>JRF</td>
<td>2015</td>
<td>15 (100%)</td>
<td>6 (40%)</td>
<td>0/3</td>
<td>1/3</td>
<td>3/5</td>
<td>1/2</td>
<td>1/2</td>
</tr>
<tr>
<td>Budget Line for Immunization</td>
<td>Countries have a budget line for vaccine procurement for routine immunization</td>
<td>GVAP Indicator (1)</td>
<td>WHO &amp; UNICEF JRF</td>
<td>2015</td>
<td>15 (100%)</td>
<td>13 (87%)</td>
<td>2/3</td>
<td>3/3</td>
<td>5/5</td>
<td>2/2</td>
<td>1/2</td>
</tr>
<tr>
<td>Public Coverage of Vaccine Expenditure</td>
<td>Countries funding ≥70% of total expenditure for routine immunization through government sources</td>
<td>Lack of established immunization indicator</td>
<td>Median coverage in sample countries</td>
<td>JRF</td>
<td>2015</td>
<td>13 (87%)</td>
<td>8 (62%)</td>
<td>0/2</td>
<td>3/3</td>
<td>3/4</td>
<td>1/2</td>
</tr>
<tr>
<td>Default History</td>
<td>Countries not defaulted on co-financing payments (up to 2015)</td>
<td>Gavi indicator of co-financing</td>
<td>Transition Reports</td>
<td>Varies</td>
<td>15 (100%)</td>
<td>9 (60%)</td>
<td>0/3</td>
<td>3/3</td>
<td>3/5</td>
<td>2/2</td>
<td>1/2</td>
</tr>
<tr>
<td>Vaccine Hesitancy</td>
<td>Countries do not identify hesitancy among vaccine users*</td>
<td>GVAP Indicator (1)</td>
<td>JRF</td>
<td>2015</td>
<td>12 (100%)</td>
<td>1 (8%)</td>
<td>0/2</td>
<td>0/2</td>
<td>0/4</td>
<td>1/2</td>
<td>0/2</td>
</tr>
<tr>
<td>Data Quality</td>
<td>Countries in which Gavi assessment teams did not report major data issues</td>
<td>GVAP Indicator (1)</td>
<td>Transition Reports</td>
<td>Varies</td>
<td>12 (80%)</td>
<td>3 (25%)</td>
<td>1/3</td>
<td>0/3</td>
<td>1/2</td>
<td>0/2</td>
<td>1/2</td>
</tr>
<tr>
<td>Communication Plan</td>
<td>Countries with a communication plan for immunization activities*</td>
<td>GVAP Indicator (1)</td>
<td>IVB Repository</td>
<td>2016</td>
<td>8 (53%)</td>
<td>3 (38%)</td>
<td>2/2</td>
<td>0/2</td>
<td>1/5</td>
<td>0/2</td>
<td>0/2</td>
</tr>
<tr>
<td>Human Resources for Immunization</td>
<td>Countries with ≤5 health care providers per 1000 population[6]</td>
<td>WHO standard of health workforce</td>
<td>World Development Indicators[4]</td>
<td>Varies</td>
<td>15 (100%)</td>
<td>5 (33%)</td>
<td>0/3</td>
<td>0/3</td>
<td>4/5</td>
<td>0/2</td>
<td>1/2</td>
</tr>
<tr>
<td>Vaccine Management</td>
<td>Countries with Effective Vaccine Management Composite Score ≥60%</td>
<td>EVG target [30]</td>
<td>IVB Repository</td>
<td>2015</td>
<td>10 (67%)</td>
<td>4 (40%)</td>
<td>0/2</td>
<td>2/2</td>
<td>2/5</td>
<td>No Data</td>
<td>0/1</td>
</tr>
<tr>
<td>Vaccine Stock-Outs</td>
<td>Countries with ≤6 stock-outs experienced between 2010 and 2015</td>
<td>Absence of country specific target – median n. of stock-outs in country sample</td>
<td>WHO &amp; UNICEF JRF Stock Out Analysis</td>
<td>2015</td>
<td>15 (100%)</td>
<td>11 (70%)</td>
<td>1/3</td>
<td>3/3</td>
<td>3/5</td>
<td>2/2</td>
<td>2/2</td>
</tr>
<tr>
<td>UN Procurement</td>
<td>Mixed- or UN-procuring countries that can continue procuring with UN Agencies post-Gavi transition without updates to regulations</td>
<td>Absence of country specific target – perceived problem</td>
<td>Transition Reports</td>
<td>Varies</td>
<td>14 (93%)</td>
<td>10 (71%)</td>
<td>2/3</td>
<td>3/3</td>
<td>3/5</td>
<td>1/2</td>
<td>2/2</td>
</tr>
<tr>
<td>Access to Timely and Affordable Supply</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Self-Procurement</td>
<td>Mixed, currently self-procuring country, or country self-procuring post-Gavi transition without procurement capacity issues</td>
<td>Absence of country specific target – perceived problem</td>
<td>Transition Reports</td>
<td>Varies</td>
<td>9 (60%)</td>
<td>2 (22%)</td>
<td>0/1</td>
<td>Not Applicable</td>
<td>1/5</td>
<td>1/1</td>
<td>0/2</td>
</tr>
<tr>
<td>Functional NRA</td>
<td>Countries with a functional NRA according to WHO-published indicators</td>
<td>GVAP Target Indicator (1)</td>
<td>RSS Database</td>
<td>2015</td>
<td>15 (100%)</td>
<td>6 (40%)</td>
<td>0/3</td>
<td>1/3</td>
<td>3/5</td>
<td>2/2</td>
<td>0/2</td>
</tr>
</tbody>
</table>

* % of countries under study (15).
*% % of countries with available data.
* WHO JRF asks countries to identify reasons for hesitancy to accept vaccines according to the national schedule. A country identifying 1+ reasons for hesitancy is classified as having a vaccine hesitancy issue. (See above-mentioned references for further information.)
assessments concluded that a majority of the study countries do not have a functional regulatory system. Transition assessments identified challenges in 53% of countries distributed across all NRA functions in all regions. Transition plans address country-specific NRA shortfalls, with a particular focus on strengthening market authorization and licensing as well as pharmacovigilance, particularly AEFI surveillance. Activities to improve NRA lot release and laboratory access functions are not specifically noted in transition plans. Nonetheless, the majority of plans call for the development of blueprints for NRA strengthening external to the transition plan. These activities may thus be described in such NRA-specific documents.

4. Discussion

Through a systematic literature review, this study confirms limited comparative analyses on immunization system performance in countries transitioning from Gavi support. Peer-reviewed and Gavi literature focus primarily on financial challenges. However, while the ability to sustainably fund immunization programmes is an area of justified concern, immunization partners have increasingly emphasized the importance of ensuring the programmatic sustainability of immunization through Gavi’s 2016–2020 Strategy [23]. Closely monitoring countries’ performance beyond financing is thus becoming key to informed policy-making, particularly for: (i) the development of a more nuanced theory of change towards sustainable immunization programmes; (ii) measurement of progress and understanding of key areas for attention and for investment; and (iii) stimulation of further discussion around eligibility criteria for external support beyond GNI.

Several existing concerns on the programmatic sustainability of immunization programmes are confirmed by a review of existing transition assessments and plans and commonly accepted immunization indicators.

4.1. Decision-making processes

The data indicates shortcomings in the use of evidence-based decision-making in transitioning countries, raising an important concern as countries lose Gavi support and further rely on autonomous decision-making for immunization policies and new vaccine introductions. Transition plans attempt to address this issue and Gavi is currently investing over 30% of its transition resources on strengthening “information, data and systems for decision-making” [24]. Despite this investment, the limited time remaining for several countries to complete their Gavi transition presents a considerable risk. Establishing systems that generate reliable data for several countries to complete their Gavi transition presents a considerable risk.

4.2. Political commitment and financial sustainability

Our analysis confirms previous conclusions on immunization financing. Country performance is difficult to assess without clear targets, yet transitioning countries encounter identifiable challenges. In particular, a review of in-country assessments reveals a lack of skills and processes to develop sound financing and resource mobilization strategies. Under its Strategic Focus Area of Sustainability, Gavi has committed to investments in financial planning and resource mobilization. Yet, at present, only 3% of transition...
investments are dedicated to supporting countries with inadequate financial planning or management and budgeting capacity [23]. Moreover, a potential shortfall of the Gavi transition process is that it tends to focus exclusively on immunization and may thus be unable to identify system-wide constraints to sustainability nor integrated and sector-wide approaches to overcome them.

Future challenges in the area of sustainable financing include: i) matching the concurrent withdrawal of other donors (e.g. the Global Fund) with national-level efforts to ensure adequate fiscal space and financing for the entire health sector; and ii) ensuring the sustainability of alternative means of support [25,26]. In fact, despite considerable investments by Gavi for developing and applying tools to assess immunization financing challenges as well as for costing immunization programmes, options to help countries mobilize national resources for immunization are underdeveloped. Positive experiences from the European and Latin American regions may prove useful in guiding policy.

4.3. Demand for and equitable delivery of vaccines

The review of vaccine hesitancy, communication for immunization, availability of skilled human resources, and effective vaccine

<table>
<thead>
<tr>
<th>Programmatic Area</th>
<th>Issue Identified in Transition Assessment</th>
<th>13 Anonymized Countries</th>
<th>Total (per area) - % of issued identified/addressed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decision-making Processes</td>
<td>NITAG not established</td>
<td>Green</td>
<td>7 (54%)</td>
</tr>
<tr>
<td></td>
<td>NITAG training</td>
<td>Green</td>
<td>3 (23%)</td>
</tr>
<tr>
<td></td>
<td>Peer-to-peer exchange</td>
<td>Green</td>
<td>3 (23%)</td>
</tr>
<tr>
<td>Political Commitment and Financial Sustainability</td>
<td>Advocacy activities for financing for immunization</td>
<td>Yellow</td>
<td>12 (50%)</td>
</tr>
<tr>
<td></td>
<td>Development of financing strategies and economic/fiscal space analyses</td>
<td>Yellow</td>
<td>9 (38%)</td>
</tr>
<tr>
<td></td>
<td>Resource mobilization strategy</td>
<td>Yellow</td>
<td>3 (13%)</td>
</tr>
<tr>
<td>Demand for and Equitable Delivery of Vaccines</td>
<td>Lack of equipment / aging equipment</td>
<td>Green</td>
<td>26 (49%)</td>
</tr>
<tr>
<td></td>
<td>Supply training</td>
<td>Green</td>
<td>8 (15%)</td>
</tr>
<tr>
<td></td>
<td>Development of a fully functional electronic data system and data analysis</td>
<td>Green</td>
<td>19 (36%)</td>
</tr>
<tr>
<td></td>
<td>Data quality monitoring</td>
<td>Green</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Population census or ensuring correct coverage estimates</td>
<td>Green</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Use of mass media, social mobilization, and communication tools</td>
<td>Yellow</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Communication training and need for communication plan</td>
<td>Yellow</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Human resources training</td>
<td>Green</td>
<td></td>
</tr>
<tr>
<td>Access to Timely and Affordable Supply</td>
<td>General procurement issue</td>
<td>Green</td>
<td>20 (49%)</td>
</tr>
<tr>
<td></td>
<td>NRA market authorization</td>
<td>Green</td>
<td>9 (22%)</td>
</tr>
<tr>
<td></td>
<td>NRA pharmacovigilence</td>
<td>Green</td>
<td>12 (29%)</td>
</tr>
<tr>
<td></td>
<td>NRA regulatory system</td>
<td>Green</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NRA lot release</td>
<td>Green</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NRA laboratory access</td>
<td>Green</td>
<td></td>
</tr>
</tbody>
</table>

Table 5: Alignment between transition assessment issues and transition plan activities, by programmatic area.

The table provides an overview of the alignment between transition assessments and transition plans for each country. Each column represents a country (n = 13), and each row indicates an issue. Green: an issue was identified in a transition assessment and was addressed in the transition plan. Yellow: an issue was not explicitly identified in the assessment but was nonetheless addressed. Red: an issue was identified in the transition assessment but not addressed in the plan. Grey: no issue identified or addressed.
management reveals critical issues across all assessments. Transition plans invest important resources to address weaknesses in these areas, but not consistently (36% of identified challenges don’t seem to be addressed). Furthermore, available time and resources may be limited and a complete interruption of external support may endanger progress. Options to continue providing limited support to countries should be explored, perhaps through stronger integration of the immunization sector with the broader health system and through longer term financial mechanisms, such as concessional loans. A concern that emerges less clearly from our review of transition assessments, but which may warrant dedicated attention moving forward, is the consistent discussion of equity issues and solutions in all countries.

4.4. Access to timely and affordable supply

An appraisal of challenges affecting access to affordable vaccine supplies provides informative results. In the area of procurement, concerns have been expressed regarding the ability of countries to continue procuring through UN agencies following the termination of Gavi support. Our analysis suggests that this problem may be limited to a few countries. In these cases, with advocacy to modify regulatory procedures, immunization partners must support countries in allowing for regulatory exceptions in the short- to medium-term.

Of greater concern is a generalized need to strengthen in-country practices for both UN and self-procurement. Considering the limited tools and support provided by the international immunization community for procurement, coupled with limited clarity on the role of different development agencies, this is a significant finding. Through transition plans, Gavi is only initiating investment in this area. Additionally, these investments may be too small to address long-term issues linked to weak pharmaceutical and procurement laws requiring several years and strong political commitment to change.

Finally, vaccine affordability has received significant attention in transition assessment discussions, with countries flagging important concerns. Yet, as a result of recent manufacturers’ commitments to affordable prices for Gavi transitioning countries, a relatively smooth transition should be possible, supported by a recent analysis [27]. It may be important to ensure available pricing commitments are promptly communicated to countries to ease anxiety and inform policy making.

While notable differences in performance by geographical region did not emerge from our results, nor are conclusions possible given the small available sample of countries, future comparative analyses could review a larger volume of data to better target investments. So far, results indicate some geographical heterogeneity in terms of the main areas of need, confirming the importance of tailored approaches for each country during the Gavi transition process. However, within each programme area studied, countries experience comparable challenges requiring similar types of support. These results encourage the current timid interest by development partners to invest in peer platforms to boost learning and leverage country knowledge and past experience—a sustainable approach to external support following Gavi transition.

In collaboration and consultation with countries, industry, and civil society organizations, global immunization partners developed a Middle Income Strategy endorsed by WHO SAGE in April 2015 to address several challenges encountered by MICs never been eligible for Gavi support. With some variability, challenges experienced by Gavi transitioning countries are similar [3]. While the MIC Strategy currently remains largely unfunded, the transition out of Gavi of several highly populated countries may improve awareness and interest in this mandate.

5. Conclusion

Middle Income Countries (MICs) losing support from Gavi, the Vaccine Alliance, require special attention to achieve Global Vaccine Action Plan (GVAP) targets. This study examined available literature and programmatic data for 15 transitioning countries documenting and beginning to address a gap in systematic analysis of programmatic performance and challenges. The analysis suggests that the transition period between a Gavi-supported programme and a self-sufficient immunization programme represents a key opportunity for targeted investments to address shortfalls, but also that a complete interruption of support following exit may jeopardize sustainability. Transitioning countries are struggling across four programmatic areas: decision-making; political commitment and financial sustainability; equitable delivery of vaccines; and access to timely and affordable supply. Continued monitoring of countries’ performance beyond financing is thus key to informed policy-making on sustainability of immunization efforts spurred by external donor support. Development of a shared theory of change towards sustainable immunization programmes and a related monitoring and evaluation framework would allow clearer measurement of progress, gaps, and understanding of key areas for future investment.

Acknowledgements

The authors would like to thank Juliette Puret for early data collection and input; Khaem Alireza, Sarah Alkenbrack, Logan Brenzel, Thomas Cherian, Adam Cohen, Santiago Cornejo, Laure Dumoldar, Ulla Griffiths, Xiao Xian Huang, Patrick Lydon, Thomas O’Connel, Minal Patel, Claudio Politi, and Kamel Senouci, for helpful discussions and suggestions; and Carmen Au for copy-editing.

Conflict of interest

All authors declare no conflicts of interest.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.vaccine.2018.06.012.

References
